Rallybio Corporation - RLYB Total Enterprise Value

Rallybio Corporation (RLYB) focuses on therapies for rare fetal blood pathologies for perinatal centers. This price chart illustrates the enterprise value, which stands at -7.72. Business revenues rely on grants while the development of drugs for hematological diseases continues. The company is currently implementing a partnership strategy with pharma behemoths as it progresses through the initial stage of phase II clinical trials for its innovative products.

RLYB (Rallybio Corp) Total Company Value history from 11/23/2025 to 10/30/2026

Rallybio (RLYB) - metric breakdowns and financial figures

- stock price and consensus target price:

Price Chart Rallybio Corp|RLYB - Consensus Target

- issuer market value details:

Market Value Rallybio|RLYB - Enterprise Value

- book capitalization data:

Net Assets per Single Share Rallybio|RLYB - Company Book Value|Market Capitalization to Net Assets rallybio.com|RLYB - Company Total Assets

- business debt structure and liquidity details:

- net income and valuation multiples indicators:

RLYB - Net Income

Analysis of all company metrics:Rallybio Corporation

Rallybio Corporation (RLYB) specializes in developing biologics for the treatment of rare pathologies protected by strict FDA patents. The EV trend reflects the current cost of a full business buyout. The formula combines market capitalization with net debt, excluding cash from the calculation. This allows for an assessment of the asset's real price regardless of liquidity. Growth in this metric signals a revaluation of the niche, necessitating caution during a shift in the market cycle.

Competitors of Rallybio Corporation (RLYB)

Haleon PLC - Total Company Value|KVUE: Real Price to Acquire Entire Company|Total Enterprise Value Verona Pharma Inc.|MENS: Enterprise Value|LGND (ligand.com) - Total Company Value|Total Company Value Amneal|Perrigo Company PLC - Full Business Value|Enterprise Value ALVO|LQDA (Liquidia Inc.) - Value Adjusted for Debt and Cash|Enterprise Value GLPG (Galapagos NV)|Enterprise Value anipharmaceuticals.com ANIP|MNKD - Total Company Value|Value Adjusted for Debt and Cash AMPH (Amphastar Pharmaceuticals Inc)|Pacira (PCRX) - Total Company Value|Real Price to Acquire Entire Company ARS Corp|TBPH (Theravance Biopharma) - Enterprise Value|Enterprise Value aquestive.com|Real Price to Acquire Entire Company SCPH (scPharmaceuticals Inc.)|TECX (tectonictx.com) - Value Adjusted for Debt and Cash|Total Company Value Tonix Pharmaceuticals Inc. TNXP|SXT Pharmaceuticals (SXTC) - Total Enterprise Value|EPRX: Real Price to Acquire Entire Company|bioharvest.com - Aggregate Business Value|EXOZ: Enterprise Value|Oramed Pharmaceuticals Inc. - Value Adjusted for Debt and Cash|ENTX (Entera Bio Ltd) - Enterprise Value|Total Enterprise Value MindWalk Therapeutics HYFT|Total Company Value ABVC BioPharma (ABVC)|CPIX (cumberlandpharma.com) - Value Adjusted for Debt and Cash|Total Company Value Quantum BioPharma QNTM|Value Adjusted for Debt and Cash FGEN|Telomir Pharma - Enterprise Value|RANI - Enterprise Value|synergychc.com (SNYR) - Total Company Value|LEXX (Lexaria Bioscience Corp.) - Total Company Value|Total Company Value Pulmatrix|Total Company Value PTHL|Real Price to Acquire Entire Company APM (Aptorum Group Limited)|LYRA - Total Enterprise Value|Enterprise Value IBO (Impact BioMedical)|TNF Pharmaceuticals Inc. - Total Company Value|cbdMD Corp - Enterprise Value|Company Buyout Price PainReform Ltd PRFX|altamiratherapeutics.com (CYTO) - Total Company Value|Total Enterprise Value Lipella Pharma (LIPO)|Real Price to Acquire Entire Company OPTN|PIRS: Value Adjusted for Debt and Cash|Enterprise Value PROC|Real Price to Acquire Entire Company Petros Pharmaceuticals Inc PTPI|Total Company Value Qilian International Holding Group Limited QLI|ACELYRIN Inc. (SLRN) - Total Enterprise Value|TFFP - Total Company Value